CN105358713B - 与克罗恩病相关的tnfsf15和dcr3的变体 - Google Patents

与克罗恩病相关的tnfsf15和dcr3的变体 Download PDF

Info

Publication number
CN105358713B
CN105358713B CN201480038133.6A CN201480038133A CN105358713B CN 105358713 B CN105358713 B CN 105358713B CN 201480038133 A CN201480038133 A CN 201480038133A CN 105358713 B CN105358713 B CN 105358713B
Authority
CN
China
Prior art keywords
seq
variants
tnfsf15
subject
dcr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480038133.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105358713A (zh
Inventor
D·P·麦戈文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CN105358713A publication Critical patent/CN105358713A/zh
Application granted granted Critical
Publication of CN105358713B publication Critical patent/CN105358713B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480038133.6A 2013-05-17 2014-05-16 与克罗恩病相关的tnfsf15和dcr3的变体 Active CN105358713B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease

Publications (2)

Publication Number Publication Date
CN105358713A CN105358713A (zh) 2016-02-24
CN105358713B true CN105358713B (zh) 2020-02-28

Family

ID=51899024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038133.6A Active CN105358713B (zh) 2013-05-17 2014-05-16 与克罗恩病相关的tnfsf15和dcr3的变体

Country Status (7)

Country Link
US (4) US20160090629A1 (https=)
EP (3) EP3498867B1 (https=)
JP (5) JP6482533B2 (https=)
KR (4) KR20230093538A (https=)
CN (1) CN105358713B (https=)
ES (1) ES2894963T3 (https=)
WO (1) WO2014186750A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2014186750A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
AU2019336798B2 (en) * 2018-09-07 2025-07-17 The Children's Hospital Of Philadelphia Compositions and methods for the diagnosis and treatment of lymphatic system disorders
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
EP4056232A4 (en) * 2019-09-13 2023-09-13 Kyowa Kirin Co., Ltd. DCR3 VARIANT
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009105590A3 (en) * 2008-02-19 2010-01-07 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
KR20140104344A (ko) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Ｔ 세포 매개성 질병의 병증을 개선하기 위한 ｔｌ１ａ-ｄｒ３의 상호작용의 차단 및 그것의 항체
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
SG11201401536QA (en) 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
WO2014186750A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009105590A3 (en) * 2008-02-19 2010-01-07 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Association of TNFSF15 with Crohn’s Disease in Koreans;Suk-Kyun Yang MD等;《Nature》;20080601;第103卷;第1437-1442页 *

Also Published As

Publication number Publication date
KR20160009582A (ko) 2016-01-26
EP3988673A3 (en) 2022-08-03
JP2025023316A (ja) 2025-02-14
EP2997165A2 (en) 2016-03-23
KR20250130857A (ko) 2025-09-02
JP2016526875A (ja) 2016-09-08
KR20230093538A (ko) 2023-06-27
JP2018148931A (ja) 2018-09-27
US20180230543A1 (en) 2018-08-16
EP3498867A1 (en) 2019-06-19
EP3988673A2 (en) 2022-04-27
JP2020127437A (ja) 2020-08-27
WO2014186750A2 (en) 2014-11-20
JP2022111329A (ja) 2022-07-29
EP2997165A4 (en) 2017-03-08
US20210371931A1 (en) 2021-12-02
KR20210107176A (ko) 2021-08-31
EP3498867B1 (en) 2021-09-29
JP6482533B2 (ja) 2019-03-13
ES2894963T8 (es) 2022-02-24
US20250243548A1 (en) 2025-07-31
CN105358713A (zh) 2016-02-24
ES2894963T3 (es) 2022-02-16
WO2014186750A3 (en) 2015-01-08
US12281359B2 (en) 2025-04-22
US20160090629A1 (en) 2016-03-31
KR102295125B1 (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
CN105358713B (zh) 与克罗恩病相关的tnfsf15和dcr3的变体
KR20180127416A (ko) Rnaset2를 통한 염증성 장 질환의 진단 방법
CA2938731A1 (en) Methods of treating alzheimer's disease
Zhang et al. Polymorphisms in the interleukin 18 receptor 1 gene and tuberculosis susceptibility among Chinese
CN103667326B (zh) 高血压易感基因组的鉴定
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
Anousha et al. Association study of estrogen receptor alpha gene polymorphisms with spontaneous abortion: is this a possible reason for unexplained spontaneous abortion?
Kim et al. Combined effect of tumour necrosis factor‐α and interleukin‐13 polymorphisms on bronchial hyperresponsiveness in Korean children with asthma
Qu et al. Association of ADAM33 polymorphisms with childhood asthma in a northern Chinese population
CN102808030A (zh) 单核苷多态性rs3888188在检测结核病易感性中的应用
Szczepańska et al. Involvement of vascular endothelial growth factor− 460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis
AU2020356429A1 (en) Method for determining the risk of incidence of a care-associated infection in a patient
CN104404044B (zh) 与心肌梗死易感相关的anril基因外显子区单核苷酸多态位点的检测方法及其应用
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
RU2548784C1 (ru) Способ прогнозирования риска развития шизофрении
Guo et al. Association between XRCC3 Thr241Met polymorphism and risk of osteosarcoma in a Chinese population
KR101883657B1 (ko) 단일염기다형성에 의한 심방세동의 예측 또는 진단에 관한 정보 제공 방법
CN105765077B (zh) 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒
Kaur et al. Effect of Interleukin 28B SNP rs12979860 Genotype on Viral Load in Hepatitis C Virus in Kolar Population, Karnataka, India.
Devinder et al. Effect of Interleukin 28B SNP rs12979860 Genotype on Viral Load in Hepatitis C Virus in Kolar Population, Karnataka, India
KR101158908B1 (ko) 아스피린 불내성 천식의 위험성과 연관된 ｃｅｐ68 유전자 변이체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant